We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Novo-N.Dkk1'b' | LSE:NVOB | London | Ordinary Share | DK0060102614 | DKK1 SER'B' |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Treasury Stock Status regarding Novo Nordisk's holding of its own shares (31 December 2008) In continuation of the company's announcement dated 7 August 2008 concerning a planned share repurchase programme, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 December 2008 owned 25,721,095 of its own B shares of DKK 1, corresponding to a total nominal value of DKK 25,721,095 or 4.06% of the total share capital. In the fourth quarter of 2008 a total of 4,186,000 B shares were repurchased, and 1,454,365 B shares were disposed of to employees in connection with employee incentive programs. About Novo Nordisk Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com. For further information please contact: Media: Outside North America: Mette Kruse Danielsen Tel: (+45) 4442 3883 E-mail: mkd@novonordisk.com In North America: Sean Clements Tel: (+1) 609 514 8316 E-mail: secl@novonordisk.com Investors: Mads Veggerby Lausten Tel: (+45) 4443 7919 E-mail: mlau@novonordisk.com Hans Rommer Tel: (+45) 4442 4765 E-mail: hrmm@novonordisk.com Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 E-mail: krop@novonordisk.com Company Announcement no 1 / 2009 This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
1 Year Novo-N.Dkk1'b' Chart |
1 Month Novo-N.Dkk1'b' Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions